Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VERTEX PHARMACEUTICALS

(VRTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Vertex Pharmaceuticals Up Over 7%, Best Performer in The S&P 500 and Nasdaq 100 So Far Today -- Data Talk

12/01/2021 | 11:22am EST

Vertex Pharmaceuticals Incorporated (VRTX) is currently at $200.44, up $13.50 or 7.22%

-- Would be highest close since Aug. 25, 2021, when it closed at $201.33

-- On pace for largest percent increase since April 2, 2020, when it rose 7.4%

-- Currently up two of the past three days

-- Down 15.19% year-to-date; on pace for worst year since 2016, when it fell 41.45%

-- Down 33.87% from its all-time closing high of $303.10 on July 20, 2020

-- Down 11.58% from 52 weeks ago (Dec. 2, 2020), when it closed at $226.70

-- Down 16.94% from its 52-week closing high of $241.31 on Jan. 25, 2021

-- Up 13.24% from its 52-week closing low of $177.01 on Oct. 5, 2021

-- Traded as high as $200.68; highest intraday level since Sept. 1, 2021, when it hit $202.55

-- Up 7.35% at today's intraday high; largest intraday percent increase since April 6, 2020, when it rose as much as 7.7%

-- Best performer in the S&P 500 today

-- Best performer in the Nasdaq 100 today

All data as of 10:59:52 AM ET

Source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

12-01-21 1122ET

Stocks mentioned in the article
ChangeLast1st jan.
VERTEX PHARMACEUTICALS 3.30% 234.06 Delayed Quote.6.58%
All news about VERTEX PHARMACEUTICALS
01/12Vertex Pharmaceuticals - European Commission Approves KAFTRIO (ivacaftor/tezacaftor/ele..
AQ
01/11Vertex's Cystic Fibrosis Combo Gets Extended EU Nod For Treating Children
MT
01/11Vertex Secures European Commission's Approval for Kaftrio With Ivacaftor as Treatment f..
MT
01/11European Commission Approves KAFTRIO« (ivacaftor/tezacaftor/elexacaftor) in Combination..
BU
01/11Vertex Pharmaceuticals Incorporated announces European Commission Approves KAFTRIO« (iv..
CI
01/06RBC Raises Price Target on Vertex Pharmaceuticals to $268 From $265, Maintains Outperfo..
MT
01/04Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10
BU
2021Diversified Healthcare Trust's Sale of 35% Stake in Boston Properties Lifts Liquidity A..
MT
2021Diversified Healthcare Trust to Sell 35% Stake in Joint Venture for $378 Million
MT
2021Wells Fargo Reinstates Vertex Pharmaceuticals With Overweight Rating, $270 Price Target
MT
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 7 501 M - -
Net income 2021 2 296 M - -
Net cash 2021 8 318 M - -
P/E ratio 2021 26,6x
Yield 2021 -
Capitalization 59 510 M 59 510 M -
EV / Sales 2021 6,82x
EV / Sales 2022 5,77x
Nbr of Employees 3 400
Free-Float -
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 234,06 $
Average target price 263,74 $
Spread / Average Target 12,7%
EPS Revisions
Managers and Directors
Reshma Kewalramani President, Chief Executive Officer & Director
Charles F. Wagner Chief Financial Officer & Executive Vice President
Jeffrey M. Leiden Executive Chairman
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
VERTEX PHARMACEUTICALS6.58%59 510
GILEAD SCIENCES, INC.-1.16%90 027
REGENERON PHARMACEUTICALS-2.58%64 327
WUXI APPTEC CO., LTD.-3.88%52 722
BIONTECH SE-23.97%47 338
BEIGENE, LTD.-11.92%24 519